Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 7,725,000	$ 5,711,000
Accounts receivable, net		12,000
Prepaid expenses and other current assets	264,000	590,000
Total current assets	7,989,000	6,313,000
Property and equipment, net	847,000	1,072,000
In process research and development	4,661,000	10,461,000
Acquired patents, net	284,000	307,000
Total assets	13,781,000	18,153,000
Current liabilities
Accounts payable and accrued expenses	949,000	1,617,000
Deferred revenue	20,000
Accrued compensation	1,145,000	895,000
Dividends payable	38,000	38,000
Insurance premium liability	20,000	185,000
Note payable	305,000	803,000
Total current liabilities	2,477,000	3,538,000
Derivative liabilities	400,000	2,443,000
Deferred tax liability	1,147,000	2,449,000
Total liabilities	4,024,000	8,430,000
Series B redeemable convertible preferred stock
$0.01 par value; no shares authorized at September 30, 2017 and December 31, 2016; no shares issued and outstanding at September 30, 2017 and December 31, 2016
Stockholders' equity
Common stock, $0.01 par value; 67,000,000 shares authorized at September 30, 2017 and December 31, 2016; 9,325,595 and 1,648,751 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	93,000	16,000
Additional paid-in capital	401,518,000	391,067,000
Accumulated deficit	(391,854,000)	(381,360,000)
Total stockholders' equity	9,757,000	9,723,000
Total liabilities, Series B redeemable convertible preferred stock and stockholders' equity	$ 13,781,000	$ 18,153,000